3andMe will host a virtual research and development day next week to discuss announcements that include taking our first wholly-owned drug into a phase 1 clinical trial, as well as a new FDA authorization to report on genetic health risks for hereditary prostate cancer.
Speakers for the virtual event include CEO and Co-Founder Anne Wojcicki, as well as Kenneth Hillian, Head of 23andMe Therapeutics. Along with them will be a presentation by Adam Auton, Vice President for Human Genetics, where he will explain in more detail how the Therapeutics team uses genetic and phenotypic data in the drug discovery process. Also on hand from the Therapeutics team will be Jennifer Low, Head of Therapeutics Development, and Joe Aaron, Chief Scientific Officer.
Beyond the presentations on drug discovery, the event will also include discussions on consumer product development with comments from Paul Johnson, the Vice President and General Manager of the consumer division of the company.
The event is scheduled for 8:00 a.m. to 11:30 am Pacific Time on Tuesday, January 18, 2022. The webcast event can be accessed on the day of the event at https://investors.23andme.com/news-events/events-presentations. A webcast replay will be available at the same address for a limited time within 24 hours after the event.